The FDA just slammed the door on its booming weight-loss drug business--but Hims & Hers has a bold new strategy.
Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...
The massive crash came after the US Food and Drug Administration (FDA) website showed the end of the shortage of Novo Nordisk ...
Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...
Hims & Hers Health, Inc. stock surged 1,000% with strategic growth, but high valuation & short interest suggest taking ...
Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...
Hims & Hers is expanding its offerings through the Trybe Labs deal after it added compounded weight loss drugs.
24/7 Wall St. on MSN3h
Hims & Hers (HIMS) Down 21% – Is the GLP-1 Gravy Train Over?Shares of Hims & Hers Health (NYSE:HIMS) are down about 21%, or $14. All on news the Ozempic shortage is over. Key Points ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback